Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.
Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, Vergara A, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Muñoz J, Fernandez P, Geijo P, de Castro ER, Diz J, Casado A, Torres C. Podzamczer D, et al. Among authors: antela a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19814. doi: 10.7448/IAS.17.4.19814. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397558 Free PMC article.
[Spanish recommendations for proper use of enfuvirtide].
Ribera E, Moreno S, Viciana P, Echevarría S, Flores J, Francés A, Gómez-Sirvent JL, González J, Hernández-Quero J, Lozano F, Mallolas J, Muñoz A, Ocampo A, Portilla J, Pulido F, Rivero A, Santos J, Soriano V, Antela A, Arazo P, Arribas JR, Cervantes M, Domingo P. Ribera E, et al. Among authors: antela a. Enferm Infecc Microbiol Clin. 2007 Feb;25(2):131-42. doi: 10.1157/13098573. Enferm Infecc Microbiol Clin. 2007. PMID: 17288910 Review. Spanish.
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].
Llibre JM, Antela A, Arribas JR, Domingo P, Gatell JM, López-Aldeguer J, Lozano F, Miralles C, Moltó J, Moreno S, Ortega E, Riera M, Rivero A, Villalonga C, Clotet B. Llibre JM, et al. Among authors: antela a. Enferm Infecc Microbiol Clin. 2010 Nov;28(9):615-20. doi: 10.1016/j.eimc.2010.08.004. Enferm Infecc Microbiol Clin. 2010. PMID: 20888082 Review. Spanish.
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.
Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M, The Toral Study Group. Podzamczer D, et al. Among authors: antela a. Curr HIV Res. 2012 Dec;10(8):673-8. doi: 10.2174/157016212803901428. Curr HIV Res. 2012. PMID: 23061598
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, Girard PM, Henry K, Nguyen T, Piontkowsky D, Garner W, White K, Guyer B. Pozniak A, et al. Among authors: antela a. Lancet Infect Dis. 2014 Jul;14(7):590-9. doi: 10.1016/S1473-3099(14)70796-0. Epub 2014 Jun 5. Lancet Infect Dis. 2014. PMID: 24908550 Clinical Trial.
Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.
Carrero-Gras A, Antela A, Muñoz-Rodríguez J, Díaz-Menéndez M, Viciana P, Torrella-Domingo A, Sanz-Moreno J, Téllez-Molina MJ, Moreno J, Hernández-Quero J, Pérez-Hernández IA, Domingo-Pedrol P. Carrero-Gras A, et al. Among authors: antela a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19819. doi: 10.7448/IAS.17.4.19819. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397563 Free PMC article.
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group. Perez-Molina JA, et al. Among authors: antela a. Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062881 Clinical Trial.
191 results